Literature DB >> 30139725

Initiative to reduce aztreonam use in patients with self-reported penicillin allergy: Effects on clinical outcomes and antibiotic prescribing patterns.

Anthony Phan1, Bryan Allen2, Kevin Epps1, Maryam Alikhil1, Katherine Kamataris1, Calvin Tucker1.   

Abstract

PURPOSE: Evaluation of the clinical impact of a pharmacist led-penicillin allergy assessment initiative to enhance antibiotic selection is reported.
METHODS: A retrospective analysis was conducted on patients with a self-reported penicillin allergy (SRPA) at a 529-bed community teaching hospital and compared clinical response rate before and after implementation of a penicillin allergy assessment initiative, consisting of pharmacy staff education and pocket card development. Patients admitted with SRPA who received antibiotics with gram-negative coverage for at least 48 hours were included. The primary outcome was the clinical response rate of penicillin-allergic patients determined preimplementation and postimplementation of the initiative and was based upon improvement in signs and symptoms of infection. Secondary outcomes included antibiotics used, antibiotic durations, length of stay, survival rate, antibiotic discontinuation rate, and Clostridium difficile infection rate.
RESULTS: A total of 280 patients were reviewed. Clinical response rate improved after implementation of the initiative (p = 0.047). There were significant differences in the type of antibiotics prescribed between the preimplementation group and the postimplementation group: increased cephalosporin use (p < 0.001), decreased aztreonam use (p = 0.017), and lower fluoroquinolone use (p = 0.008). Median length of stay (p = 0.943), in-hospital mortality rate (p = 0.173), and C. difficile infection rate (p = 0.426) were similar before and after implementation of the initiative.
CONCLUSION: After implementation of an initiative to encourage the use of cephalosporins rather than aztreonam in patients with SRPA, the rate of clinical response and cephalosporin use increased and rates of exposure to aztreonam and fluoroquinolones decreased.
Copyright © 2018 by the American Society of Health-System Pharmacists, Inc. All rights reserved.

Entities:  

Keywords:  antibiotics; antimicrobial stewardship; aztreonam; beta-lactam; drug allergy; infectious disease

Mesh:

Substances:

Year:  2018        PMID: 30139725     DOI: 10.2146/ajhp170400

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  4 in total

1.  Penicillin Allergy Delabeling: A Multidisciplinary Opportunity.

Authors:  Mary L Staicu; David Vyles; Erica S Shenoy; Cosby A Stone; Taylor Banks; Kristin S Alvarez; Kimberly G Blumenthal
Journal:  J Allergy Clin Immunol Pract       Date:  2020-10

Review 2.  Acute care beta-lactam allergy pathways: approaches and outcomes.

Authors:  Anna R Wolfson; Emily M Huebner; Kimberly G Blumenthal
Journal:  Ann Allergy Asthma Immunol       Date:  2019-04-19       Impact factor: 6.347

3.  Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a Tertiary Care Hospital.

Authors:  Nicholas A Turner; Rebekah Wrenn; Christina Sarubbi; Renee Kleris; Patricia L Lugar; Christine Radojicic; Rebekah W Moehring; Deverick J Anderson
Journal:  JAMA Netw Open       Date:  2021-05-03

4.  Short and long term impact of combining restrictive and enabling interventions to reduce aztreonam consumption in a community hospital.

Authors:  Dviti Mody; Christopher Burke; Quentin Minson
Journal:  Int J Clin Pharm       Date:  2021-03-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.